Skip to content

Author

L. Remolí-Sargues

We have 2 of 41 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Comparison of Choroidal Vascularity Index Between Type 1 and Type 2 Macular Neovascularization Before and After Anti-VEGF Therapy.

PURPOSE To compare choroidal structural features and visual and anatomical outcomes between type 1 and type 2 macular neovascularization (MNV) at baseline and following anti-vascular endothelial growth factor (anti-VEGF) therapy. METHODS This retrospective study included 56 eyes of 44 patients with treatment-naïve ne...

L. Remolí-Sargues, C. Monferrer-Adsuara, V. Castro-Navarro et al. · 0 citations
Review Open access Sep 2026

From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are leading causes of visual impairment and require long-term intravitreal anti-vascular endothelial growth factor (VEGF) therapy. However, treatment burden and suboptimal real-world outcomes remain major challenges. Faricimab is a bis...

J. Ruíz-Moreno, C. Bernal-Morales, Olivia Esteban-Floría et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.